StephenBruceStrumMDFACP

PubMed

• Optimized 18F-FDG PET-CT Method to Improve Accuracy of Diagnosis of Metastatic Cancer.
  Richard Black, Jelle Barentsz, David Howell, David G Bostwick, Stephen B Strum> ;Diagnostics. 2023 Apr 28
• Patients Managing Medications and Reading Their Visit Notes.
  Stephen B. Strum> ;Annals of Internal Medicine. 2019 Nov 19
• Michael's Testimonial.
  Stephen B. Strum> ;Annals of Internal Medicine. 2019 Apr 2
• Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer.
  Stephen B. Strum> ;Annals of Internal Medicine. 2018 Mar 20
• 1 citations
  The Scientific Basis of Guideline Recommendations on Sugar Intake.
  Stephen B. Strum> ;Annals of Internal Medicine. 2017 Aug 1
• 1 citations
  Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care
  Stephen B. Strum, Mark C. Scholz> ;JAMA Oncology. 2016 May 1
• 35 citations
  Case Report: Sodium dichloroacetate (DCA) inhibition of the “Warburg Effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progr...
  Stephen B. Strum, Örn Adalsteinsson, Richard R. Black, Dmitri Segal, Nancy L. Peress, James Waldenfels> ;Journal of Bioenergetics and Biomembranes. 2013 May 8
• Erratum to: Case Report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after d...
  Strum, S. B.,Adalsteinsson, O.,Black, R. R.,Segal, D.,Peress, N. L.,Waldenfels, J.> ;J. Bioenerg. Biomembr.. 2013 May 09
• 2 citations
  Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
  Mark C. Scholz, Meg K. Groom, Andrew J. Kaddis, Stephen B. Strum, Robert I. Jennrich, Duke K. Bahn, Patricia J. Chang, Lauren K. Becker, Richard Y. Lam> ;The Prostate. 2013 Jan 1
• 5 citations
  Inviting Patients to Read Doctors' Notes
  Stephen B. Strum> ;Annals of Internal Medicine. 2012 Apr 17
• 6 citations
  Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer.
  Mark C. Scholz, Richard Y. Lam, Stephen B. Strum, Dean J. LaBarba, Lauren K. Becker, Patricia J. Chang, Nojan Farhoumand, Robert I. Jennrich> ;Clinical Genitourinary Cancer. 2011 Dec 1
• 28 citations
  State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer
  Stijn W.T.P.J. Heijmink, Jurgen J. Fütterer, S.S. Strum, Wim J.G. Oyen, Ferdinand Frauscher, J.A. Witjes, Jelle O. Barentsz> ;Acta Oncologica. 2011 May 23
• 635 citations
  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis
  Anke M. Hövels, Roel A. M. Heesakkers, Eddy M. M. Adang, Gerrit J. Jager, S. Strum, Yvonne L. Hoogeveen, Johan L. Severens, Jelle O. Barentsz> ;Clinical Radiology. 2008 Apr 1
• 11 citations
  Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceutic...
  Mark C. Scholz, Richard Y. Lam, Stephen B. Strum, Robert I. Jennrich, Henry Johnson, Tom Trilling> ;Urology. 2007 Sep 1
• Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression.
  Scholz MC, Lam R, Guess B, Strum S, Johnson H, Jenrrich R> ;J. Clin. Oncol.. 2006-06-20
• 25 citations
  Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
  Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, Henry Johnson, Brad W. Guess, Richard Y. Lam> ;The Journal of Urology. 2006 May 1
• 32 citations
  LONG-TERM OUTCOME FOR MEN WITH ANDROGEN INDEPENDENT PROSTATE CANCER TREATED WITH KETOCONAZOLE AND HYDROCORTISONE
  Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, Stanley A. Brosman, Henry Johnson, Richard Y. Lam> ;The Journal of Urology. 2005 Jun 1
• Maniacs, Malignancy, Medicine
  Stephen B. Strum> ;The Oncologist. 2002 Feb 1
• 1 citations
  Re: Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
  Mark C. Scholz, Stephen B. Strum> ;The Journal of Urology. 2000 Apr 1
• 50 citations
  Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
  Stephen B. Strum, Mark C. Scholz, Jonathan E. McDermed> ;The Oncologist. 2000 Feb 1
• 84 citations
  Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system.
  Stephen B. Strum, Jonathan E. McDermed, A Korn, C Joseph> ;Journal of Clinical Oncology. 1986 Apr 1
• 10 citations
  Clinical Pharmacokinetics of High-Dose Metoclopramide in Cancer Patients Receiving Cisplatin Therapy
  Jonathan E. McDermed, Jordan L. Cohen, Corrine Joseph, Stephen B. Strum> ;Journal of Clinical Oncology. 1985 Oct 1
• 4 citations
  Intrathoracic Hodgkin's disease. A case presentation with multiple pulmonary nodules in the absence of mediastinal or hilar node disease.
  Stephen B. Strum, Alan Weiss, Jonathan E. McDermed, Victor J. Rosen> ;Cancer. 1985 Oct 15
• 4 citations
  Drug Extravasation and the Port-a-Cath System
  Stephen B. Strum, Jonathan E. McDermed> ;Annals of Internal Medicine. 1985 Sep 1
• 40 citations
  High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a sin...
  S B Strum, J E McDermed, D F Liponi> ;Journal of Clinical Oncology. 1985 Feb 1
• Join now to see all

Journal Articles

• Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care  
  Strum SB, Scholz MC, JAMA Oncol, 1/1/2016
• Re: Is Prostate-Specific antigen screening "Proven Ineffective Care"?  
  Strum SB, Ann Int Med, 1/1/2016
• Re: Transparent electronic health records and lagging laws  
  Strum SB, Ann Int Med, 1/1/2016
• Re: Preventable incidence and mortality of carcinoma associated  
  Strum SB, JAMA Oncol, 1/1/2016
• Case Report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease pr...  
  Strum SB, Adalsteinsson O, Black RR, Segal D, Peress NL, Waldenfels J, J Bioenerg Biomembr, 1/1/2013
• Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study  
  Scholz MC, Groom MK, Kaddis AJ, et al, Prostate, 1/1/2013
• Inviting patients to read doctors' notes  
  Strum SB, Annals Of Internal Medicine, 1/1/2012
• State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer  
  Heijmink SW, Futterer JJ, Strum SS, Oyen WJ, Frauscher F, Witjes JA, Barentsz JO, Acta Oncol, 1/1/2011
• Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer  
  Scholz MC, Lam RY, Strum SB, Labarba DJ, Becker LK, Chang P, Farhoumand N, Jennrich RI, Clinical Genitourinary Cancer, 1/1/2011
• The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis  
  Hovels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO, Clin Radiology, 1/1/2008
• Prostate cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone inactivating pharmaceuticals  
  Scholz M, Lam R, Strum S, et al, Urology, 1/1/2007
• Ultra-sensitive PSA nadir on testosterone-inactivating pharmaceuticals accurately predicts early prostate cancer progression  
  Scholz MC, Lam RY, Jennrich RI, Strum, S.B. et al, J Clin Oncol, 1/1/2006
• Low-dose single-agent weekly docetaxel (taxotere) is effective and well tolerated in elderly men with prostate cancer  
  Scholz MC, Guess B, Barrios F, Strum S, Leibowitz R, Proc Amer Soc Clin Oncol, 1/1/2001
• Intermittent Hormone Blockade: optimal induction duration and predictive factors for prolonged time off hormone blockade  
  Strum SB, McDermed JE, Scholz MC, Oncologist, 1/1/2000
• High-Dose Ketoconazole and hydrocortisone (Keto) for hormone refractory prostate cancer (HRPC)  
  Scholz M, Strum S, Mittelman P, Proc Amer Soc Clin Oncol, 1/1/2000
• Modified citrus pectin slows PSA doubling time: a pilot clinical trial  
  Strum SB, Scholz M, McDermed J, McCulloch M, Eliaz I, International Conference on Diet and Prevention of Cancer, 1/28/1999
• Predictors of prolonged time off intermittent androgen deprivation (lAD) for prostate cancer (PC): attainment and maintenance of an undetectable PSA (UD-PSA) for 1 yea...  
  Lindberg P, Strum S, Madsen L, McDermed J, Proc Amer Soc Clin Oncol, 1/1/1999
• Intermittent androgen deprivation (IAD) therapy for prostate cancer (PC): PSA response on cycle 1 (C1) can predict response on subsequent cycles  
  Scholz M, Strum S, Madsen L, McDermed J, Proc Amer Soc Clin Oncol, 1/1/1999
• Intermittent androgen deprivation (lAD) with finasteride (F) given during the induction and maintenance periods results in prolonged time off lAD in patients with loca...  
  Strum S, McDermed J, Madsen L, Scholz M, Proc Amer Soc Clin Oncol, 1/1/1999
• Intermittent androgen deprivation (IAD) with finasteride (F) during induction and maintenance permits prolonged time off IAD in localized prostate cancer (LPC)  
  Scholz M, Strum S, McDermed J, J Urol, 1/1/1999
• Re: recovery of spontaneous erectile function after nerve- sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: re...  
  Scholz M, Strum S, J Urol, 1/1/1999
• editorial re: Moyad MA, Pienta KJ, Montie JE: Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naïve disease  
  Strum SB, J Urol, 1/1/1999
• Re: Prostate specific antigen: a decade of discovery-what we have learned and where are we going Comments on article by Polascik TJ, Oesterling JE and Partin AW  
  Scholz MC, Strum S, J Urol, 1/1/1999
• Intermittent hormone blockade (IHB): optimal induction and predictive factors for prolonged time off hormone blockade (HB)  
  Strum SB, Scholz MC, and McDermed JE, Prostate Cancer Research Institute. Xth International Congress on Hormonal Steroids, 1/17/1998
• Combined Hormone Blockade (CHB) Induction And Finasteride Maintenance (FM) Permits Discontinuation Of CHB For Prolonged Periods In Patients With Low-Volume (LV) Prosta...  
  Strum SB, Scholz MC, and McDermed JE, Prostate Cancer Research Institute. Xth International Congress on Hormonal Steroids, 1/17/1998
• Join now to see all

Books/Book Chapters

• A Primer on Prostate Cancer, The Empowered Patient's Guide 
  Strum SB, Pogliano DLLife Extension Media, Hollywood, FL2002
• A Primer on Prostate Cancer, The Empowered Patient's Guide 
  Strum SB, Pogliano DLLife Extension Media, Hollywood, FLEdition 1st,2002
• A Primer on Prostate Cancer, The Empowered Patient's Guide 
  Editors: Strum SB, Pogliano DL.Life Extension Media, Hollywood, FLEdition 2nd,2002
• Current Concepts in the Management of Leukemia and Lymphoma 
  Chapter: The staging of lymphoma 
  Page 43 - 46Allen LW, Strum SB, Ultmann JE, and Rappaport HEditors: Ultmann JE, Griem ML, Kristen WH, & Wissler RW.Springer-Verlag, New York, NY1971
• Essentials of Surgical Pathology, A Programmed Text 
  Chapter: Hematopathology 
  Page 239 - 257Variakojis D, Strum SB, and Enriques PEditors: Daniels AC, et al.1971
• Join now to see all

Abstracts/Posters

• Optimized Imaging in Prostate Cancer (PC) is Absent 95% of the Time at Diagnosis or PSA Recurrence
  Strum SB, 2nd Annual Multidisciplinary Prostate Cancer Symposium, San Francisco Marriott, San Francisco, CA, 1/24/2006
• Optimized imaging in prostate cancer (PC) is absent 95% of the time at diagnosis or PSA recurrence
  Strum SB, Scholz MC, J Clin Oncol, 1/1/2006
• Intermittent hormone blockade (IHB) in prostate cancer (PC) patients: Duration of non-detectable PSA (NDPSA) on androgen blockade relates to time off treatment
  Strum SB & Scholz MC, 7th International Congress on Anti-Cancer Treatment, Paris, France, 1/3/1997
• Prolonged non-detectable PSA (NDPSA) in PC patients treated with androgen deprivation may allow for discontinuation of hormone blockade
  Strum SB, Scholz M.C. & Strum M, International Symposium on Recent Advances in Diagnosis & Treatment of Prostate Cancer, Quebec City, Canada, 1/21/1995
• Combined Use of Biotinylated TNT-1 and I-131 Streptavidin for the Clinical Treatment of Prostate Cancer
  Epstein AL, Strum SB, Thompson LA, Khawli LA, and Mills SL, The Society of Nuclear Medicine 39th Annual Meeting, Los Angeles Convention Center, Los Angeles, CA, 1/1/1992
• Clinical pharmacokinetics (PK) of high-dose (HD) metoclopramide(MCP) in cisplatin (DDP) treated patients
  McDermed JE, Cohen JL, Joseph C, Waugh WJ, and Strum SB, Proc Am Soc Clin Oncol, 1/1/1985
• Correlative data relating serum metoclopramide (MCP) and serum cisplatin (DDP) levels: Preliminary results
  McDermed JE, Cohen JL, Huang C., Waugh WJ, and Strum SB, Proc Am Soc Clin Oncol, 1/1/1985
• Management of cisplatin (DDP) induced delayed onset nausea(N) and vomiting (V): Preliminary results with two drug regimens
  Strum SB, McDermed JE, Abrahano-Umali RA, Sanders PF, Proc Am Soc Clin Oncol, 1/1/1985
• The PORT-A-CATH (PAC) - A totally implanted catheter system
  Strum SB, McDermed JE, Korn AR, Rappaport HR, Barnes K, Proc Am Soc Clin Oncol, 1/1/1985
• A preliminary pharmacokinetic (PK) evaluation of high-dose (HD) metoclopramide (MCP) in patients (PTS) receiving cis-platinum(DDP) chemotherapy(CT)
  McDermed JE, Waugh WJ, and Strum SB, Proc Am Soc Clin Oncol, 1/1/1984
• Combination metoclopramide (MCP) and dexamethasone (DXM) An effective antiemetic regimen in outpatients receiving doxorubicin (DOX) cyclophosphamide (CYC) chemotherapy...
  Strum SB, McDermed JE, Streng BF, and McDermott NM, Proc Am Soc Clin Oncol, 1/1/1984
• A preliminary pharmacologic evaluation of high-dose intravenous metoclopramide in cancer patients
  McDermed JE, Cohen JL, Devine BJ, and Strum SB, Proceedings of the ASHP 18th Annual Midyear Clinical Meeting, Atlanta, GA, 1/9/1983
• The effectiveness of intravenous(IV) dexamethasone (DXM) as adjunctive therapy in preventing nausea (N) and vomiting (V) in patients receiving cis-platinum(DDP) chemot...
  Strum SB, and McDermed JE, Am Assoc Cancer Res, 1/1/1983
• Intravenous (IV) metoclopramide(MCP): An effective antiemetic in patients receiving non-platinum chemotherapy (CT)
  Strum SB, and McDermed JE, Proc Am Soc Clin Oncol, 1/1/1983
• HPLC assay for metoclopramide in serum
  Cohen JL, Hisayasu GH, McDermed JE, and Strum SB, 35th National Meeting, APHA Academy of Pharmaceutical Sciences, Miami Beach, FL, 1/1/1983
• Antiemetic effectiveness of intravenous metoclopramide in cis-platinum treated patients
  McDermed JE, and Strum SB, Pan Pacific II Conference, Honolulu, HI, 1/13/1982
• Effective protection with intravenous (IV) metoclopramide (MCP) against chemotherapy-induced emesis
  Strum SB & McDermed JE, Am Assoc Cancer Res, 1/1/1982
• Intravenous Metoclopramide (MCP) prevention of cis-platinum(DDP)-induced nausea and vomiting
  Strum SB, Opfell RW, McDermed JE, and Reich LP, Proc Am Soc Clin Oncol, 1/1/1981
• Metoclopramide (MCP) as an anti-emetic in cancer chemotherapy with cis-platinum(DDP)
  McDermed JE, Reich LP, Opfell RW, and Strum SB, 16th Annual American Society of Hospital Pharmacists, 1/1/1981
• Chromosome abnormalities in the peripheral blood of patients with Mycosis Fungoides
  Joseph RH, and Strum SB, Proc Am Soc Clin Oncol, 1/1/1979
• Short term intra-arterial infusion of cis-platinumdiamminedichloride (CDDP) for regional control of cancer
  Wu SGJ, Kosch A, McNamee LJ, and Strum SB, Proc Am Soc Clin Oncol, 1/1/1979
• Hydrazine sulfate in patients with neoplasia
  Strum SB, and Bierman HR, Proc Am Assoc Cancer Res, 1/1/1975
• Increased alpha-1anti-trypsin, decreased systemic fibrinolysis, hypercoaguable state and increased fibrin split products in patients with lung cancer
  Samuels AJ, Bierman HR, and Strum SB, Proc Am Soc Clin Oncol, 1/1/1975
• Oncologic applications of diagnostic ultrasound
  Krane M, Strum SB, Jaffe HL, and Bierman HR, Proc Am Soc Clin Oncol, 1/1/1975
• The late consequences of cancer therapy
  Bierman HR, and Strum SB, American College of Physicians Annual Meeting, 1/1/1975
• Join now to see all

Lectures

• Androgen Deprivation Therapy in Prostate Cancer: New Advances 
  Los Angeles, CA - 1/11/2012
• Pro-Active Integrative care in the management of prostate cancer 
  Los Angeles, CA - 1/11/2010
• Prostate MR Imaging: Is There an Added Value in Clinical Management? 
  1/30/2009
• Confessions of a Medical Heretic 
  1/23/2009
• Sharing My Experiences With Prostate Cancer 
  Bielefeld, Germany - 1/14/2009
• Talking About Prostate Cancer 
  Darmstadt, Germany - 1/13/2009
• How I Manage Prostate Cancer 
  Stuttgart, Germany - 1/11/2009
• Successful Strategies in Prostate Cancer Care 
  Munich, Germany - 1/5/2009
• Male Osteoporosis 
  Boca Raton, FL, 2008; Fullerton, CA, 2008 - 1/26/2008
• Prostate Health & Interactions With Hormonal Therapies As Men Age 
  Boca Raton, FL - 1/18/2008
• Principled Medicine & Prostate Cancer: Using Concepts to Promote Superior Medical Outcomes 
  Unity Palo Alto Community Church, Palo Alto, CA - 1/17/2008
• What Should Men Ages 35 to 55 Know About Prostate Health 
  Royal Pines Resort Hotel, Gold Coast, Ashmore, Australia - 1/15/2008
• History, Growth & Achievements of the PCRI (Prostate Cancer Research Institute) 
  Royal Pines Resort Hotel, Gold Coast, Ashmore, Australia - 1/15/2008
• Prostate Cancer as a Paradigm for Pro-Active Integrative Management (PIM) 
  Venetian Hotel, Las Vegas NV - 1/11/2008
• IAD (intermittent androgen deprivation). PSA Recurrence (PSAR) after Initial Local Rx. 
  Los Angeles, CA - 1/6/2008
• Principled Medicine: Concepts that Promote Superior Medical Outcomes in Prostate Cancer 
  Paliser Hotel, Calgary, Canada - 1/3/2008
• Low Impact Pharmaceuticals 
  LAX Marriott Hotel, Los Angeles, CA - 1/8/2007
• Primary ADT(androgen deprivation therapy) 
  LAX Marriott Hotel, Los Angeles, CA - 1/8/2007
• Winning the War Against Prostate Cancer 
  Calgary, Canada - 1/30/2006
• New Dimensions In Early Detection & Response To Treatment Of Prostate Cancer 
  Arlington Heights, IL - 1/29/2005
• How Supportive Measures Enhance Outcome in PC Patients 
  Omni Shoreham Hotel, Washington, DC - 1/18/2005
• The End of Prostate Cancer 
  Omni Shoreham Hotel, Washington, DC - 1/18/2005
• Status & Strategy in the Successful Treatment of Prostate Cancer 
  Omni Shoreham Hotel, Washington, DC - 1/17/2005
• Optimal Imaging in Prostate Cancer 
  Amsterdam, The Netherlands - 1/4/2005
• Interdisciplinary Prostate Cancer Consult for Improvement of Therapy Outcome 
  Maritim Hotel, Hannover, Germany, 2004; University Clinic Grosshadern, Munich, Germany, 2004 - 1/18/2004
• Join now to see all

Other

• Prostate Cancer. Essential Concepts for Survival 
  Strum SB, Amazon Kindle
  http://tinyurl.com/chmz45h
  1/1/2013
• Reducing prostate cancer deaths through prevention and early diagnosis 
  Strum SB, Life Extension Magazine
  1/1/2003
• The global threat of SARS 
  Strum SB, Life Extension Magazine
  1/1/2003
• How laboratory test analysis alter the course of life 
  Strum SB, Life Extension Magazine
  1/1/2003
• Boron maintains bone, joints, neurons and may reduce prostate cancer risk 
  Strum SB, Life Extension Magazine
  1/1/2003
• Prostate Cancer, Early to Advanced Disease in: Life Extension Disease Prevention and Treatment. Scientific protocols that integrate mainstream and alternative medicine 
  Strum SB, McDermed JE
  1/1/2000
• Oversimplification in cancer chemotherapy 
  Strum SB, "Letters," Internal Med News
  1/1/1978
• Join now to see all